Dusseldorf - Delayed Quote EUR
Seres Therapeutics Inc (1S9.DU)
0.0000
0.0000
(0.00%)
At close: April 17 at 7:30:21 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
--
--
--
--
144,927
Cost of Revenue
3,532
3,532
--
--
--
Gross Profit
-3,532
-3,532
--
--
--
Operating Expense
117,783
117,783
195,097
179,914
209,420
Operating Income
-121,315
-121,315
-195,097
-179,914
-64,493
Net Non Operating Interest Income Expense
3,967
3,967
4,833
-2,962
-40
Other Income Expense
-8,423
-8,423
134
-705
-1,045
Pretax Income
-125,771
-125,771
-190,130
-183,581
-65,578
Net Income Common Stockholders
136
136
-113,724
-250,157
-65,578
Diluted NI Available to Com Stockholders
136
136
-113,724
-250,157
-65,578
Basic EPS
0.00
0.00
-17.80
-46.20
-14.40
Diluted EPS
0.00
0.00
-17.80
-46.20
-14.40
Basic Average Shares
7,770.0380
155,400.7600
6,400.1640
5,403.8520
4,585.1430
Diluted Average Shares
7,770.0380
155,400.7600
6,400.1640
5,403.8520
4,585.1430
Total Operating Income as Reported
-121,315
-121,315
-195,097
-179,914
-64,493
Total Expenses
121,315
121,315
195,097
179,914
209,420
Net Income from Continuing & Discontinued Operation
136
136
-113,724
-250,157
-65,578
Normalized Income
-131,455
-131,455
-190,130
-183,581
-65,578
Interest Income
3,967
3,967
7,301
3,058
2,870
Interest Expense
--
--
2,468
6,020
2,910
Net Interest Income
3,967
3,967
4,833
-2,962
-40
EBIT
-125,771
-125,771
-187,662
-177,561
-62,668
EBITDA
-120,303
-120,303
-181,419
-170,932
-56,721
Reconciled Cost of Revenue
3,532
3,532
--
--
--
Reconciled Depreciation
5,468
5,468
6,243
6,629
5,947
Net Income from Continuing Operation Net Minority Interest
-125,771
-125,771
-190,130
-183,581
-65,578
Total Unusual Items Excluding Goodwill
5,684
5,684
--
--
--
Total Unusual Items
5,684
5,684
--
--
--
Normalized EBITDA
-125,987
-125,987
-181,419
-170,932
-56,721
12/31/2021 - 4/17/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade